Please wait while the formulary information is being retrieved.
HECTOROL (DOXERCALCIFEROL)
- Hyperparathyroidism secondary to CRF with dialysis
2 mcg/mL intravenous solution
- Infuse 2 milliliters (4 mcg) by intravenous route 3 times per week atthe end of dialysis
4 mcg/2 mL intravenous solution
- Infuse 2 milliliters (4 mcg) by intravenous route 3 times per week atthe end of dialysis
2 mcg/mL intravenous solution
- Infuse 2 milliliters (4 mcg) by intravenous route 3 times per week atthe end of dialysis
4 mcg/2 mL intravenous solution
- Infuse 2 milliliters (4 mcg) by intravenous route 3 times per week atthe end of dialysis
Hyperparathyroidism secondary to chronic renal failure
- Infuse 2 milliliters (4 mcg) by intravenous route 3 times per week atthe end of dialysis
- Infuse 2.5 milliliters (5 mcg) by intravenous route 3 times per week at the end of dialysis
- Infuse 3 milliliters (6 mcg) by intravenous route 3 times per week atthe end of dialysis
Hyperparathyroidism secondary to CRF with dialysis
- Infuse 2 milliliters (4 mcg) by intravenous route 3 times per week atthe end of dialysis
- Infuse 2.5 milliliters (5 mcg) by intravenous route 3 times per week at the end of dialysis
- Infuse 3 milliliters (6 mcg) by intravenous route 3 times per week atthe end of dialysis
- None
Contraindicated
- None
Severe
Moderate
- None
- Hypercalcemia
- Hypervitaminosis D
Contraindicated
- Hyperphosphatemia
Severe
Moderate
- Disease of liver
- Hypoparathyroidism
HECTOROL (DOXERCALCIFEROL)
- Hyperparathyroidism secondary to CRF with dialysis
- Dyspnea
- Chest pain
- Dizziness
- Edema
- Headache disorder
- Malaise
- Pruritus of skin
- Vomiting
More Frequent
Severe
Less Severe
- Abscess
- Arthralgias
- Bradycardia
- Infection
- Anorexia
- Cough
- Depression
- Dyspepsia
- Hyperphosphatemia
- Hypertonia
- Paresthesia
- Rhinitis
- Sleep disorder
- Weight gain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Hypotension
Less Severe
- Chest discomfort
- Constipation
- Hypercalcemia
- Nausea
- Stinging of skin
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Doxercalciferol (inj)
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Doxercalciferol
- Severity Level:
2
- Additional Notes: Insufficient human data available; animal data suggest no developmental toxicity
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Doxercalciferol
Other vit d analogues are excreted in breast milk; monitor for hypercalcemia.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Other vit d analogues are excreted in breast milk; monitor for hypercalcemia. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Hyperparathyroidism secondary to CRF with dialysis | |
| N25.81 | Secondary hyperparathyroidism of renal origin |
| 0-9 | A-Z |
|---|---|
| N25.81 | Secondary hyperparathyroidism of renal origin |
Formulary Reference Tool